<DOC>
	<DOCNO>NCT02336139</DOCNO>
	<brief_summary>To evaluate proportion patient undetectable HCV RNA 12 week post end treatment ( SVR12 ) follow sofosbuvir/GS-5816 therapy 12 week people chronic HCV infection recent injection drug use .</brief_summary>
	<brief_title>A Phase II Trial Sofosbuvir ( SOF ) GS-5816 People With Chronic Hepatitis C Virus Infection Recent Injection Drug Use</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>1 . Participants voluntarily sign informed consent form . 2 . 18 year age old . 3 . Chronic HCV infection define antiHCV antibody HCV RNA detection great 6 month . 4 . HCV RNA plasma ≥ 1000 IU/ml Screening . 5 . HCV genotypes 16 . 6 . Recent inject drug use ( previous 6 month ) . 7 . Compensated liver disease . 8 . Participants Fibroscan &gt; 12 KPa AFP &gt; 50 ng/mL must abdominal ultrasound CT scan without evidence hepatocellular carcinoma within 2 month prior screen . 9 . Negative pregnancy test baseline ( female childbearing potential ) . 10 . All fertile male female must use effective contraception treatment 30 day treatment end . 1 . History follow : 1 . Clinically significant illness ( HCV ) major medical disorder may interfere participant treatment , assessment compliance protocol ; participant currently evaluation potentially clinically significant illness ( HCV ) also exclude . 2 . Clinical hepatic decompensation ( i.e . ascites , encephalopathy variceal haemorrhage ) 3 . Solid organ transplant 4 . Malignancy within 5 year prior screen , exception specific cancer may cure surgical resection ( basal cell skin cancer , etc. ) . Subjects evaluation possible malignancy also exclude . 5 . Significant drug allergy ( anaphylaxis hepatotoxicity ) . 2 . Screening ECG clinically significant abnormality 3 . Any following lab parameter screen : 1 . ALT &gt; 10 x ULN 2 . AST &gt; 10 x ULN 3 . Direct bilirubin &gt; 1.5 x ULN 4 . Platelets &lt; 50,0000/μL 5 . HbA1c &gt; 8.5 % 6 . Creatinine clearance ( CLcr ) &lt; 60 mL/min 7 . Haemoglobin &lt; 11 g/dL female ; &lt; 12 g/dL male 8 . Albumin &lt; 30g/L 9 . INR &gt; 1.5 ULN unless subject know haemophilia stable anticoagulant regimen affect INR 4 . Pregnant nursing female . 5 . HIV infection HBV infection ( HBcAb HBsAg positive ) 6 . Use prohibit concomitant medication describe section 5.2 7 . Chronic use systemically administer immunosuppressive agent ( e.g . prednisone equivalent &gt; 10 mg/day ) 8 . Known hypersensitivity GS5816 , sofosbuvir ( SOF ) formulation excipients . 9 . Therapy antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) ≤6 month prior first dose study drug . 10 . Any investigational drug ≤6 week prior first dose study drug . 11 . Previous therapy sofosbuvir ( SOF ) NS5A inhibitor prior first dose study drug . 12 . Ongoing severe psychiatric disease judge treat physician . 13 . Frequent inject drug use judge treat physician compromise treatment safety . 14 . Inability unwillingness provide inform consent abide requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>